Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

被引：6
|
作者：
Richardson, Paul G. [1 ]
Sandhu, Irwindeep [2 ]
Hofmeister, Craig C. [3 ]
Orlowski, Robert Z. [4 ]
White, Darrell [5 ,6 ]
Belotti, Angelo [7 ]
Hansen, Charlotte Toftmann [8 ]
Raje, Noopur S. [9 ]
Chow, Tracy T. [10 ]
Zhou, Zehua [10 ]
Civardi, Tiziana [11 ]
Koo, Phillip [10 ]
Zhu, Yue [10 ]
Katz, Jessica [10 ]
Oriol, Albert [12 ,13 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Cross Canc Inst, Edmonton, AB, Canada
[3] Winship Canc Inst Emory Univ, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[5] Dalhousie Univ, Halifax, NS, Canada
[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy
[8] Odense Univ Hosp, Odense, Denmark
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Bristol Myers Squibb, Princeton, NJ USA
[11] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
[12] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain
[13] Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174443
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：5
相关论文
共 50 条
  • [31] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [32] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
    Jakubowiak, Andrzej J.
    White, Darrell
    Moreau, Philippe
    Facon, Thierry
    Vij, Ravi
    Kroog, Glenn Scott
    Kopit, Justin
    Singhal, Anil
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Results of Study CC-220-MM-001 Dose Expansion of Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients with Relapsed/Relapsed-Refractory Multiple Myeloma (RRMM)
    Knop, S.
    Lonial, S.
    Popat, R.
    Hulin, C.
    Jagannath, S.
    Oriol, A.
    Richardson, P. G.
    Facon, T.
    Weisel, K.
    Larsen, J. T.
    Minnema, M. C.
    Abdallah, A. -O. A.
    Badros, A. Z.
    Stadtmauer, E. A.
    Chen, M.
    Nguyen, T., V
    Amin, A.
    Peluso, T.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 247 - 247
  • [34] Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) versus LEN plus DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.
    Obeng-Kusi, Mavis
    Arku, Daniel
    Alrawashdh, Neda
    Choi, Briana
    Alkhatib, Nimer S.
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an effective salvage regimen for multiple myeloma (MM) patients relapsed and/or refractory to Daratumumab (dara)
    Brioli, A.
    Ernst, T.
    Hilgendorf, I.
    Heidel, F.
    Hunstig, F.
    Stauch, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 278 - 278
  • [36] Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len plus Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios Athanasios
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna M.
    BLOOD, 2011, 118 (21) : 1263 - 1263
  • [37] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [38] Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)
    Yimer, Habte
    Melear, Jason
    Faber, Edward
    Bensinger, William
    Burke, John M.
    Narang, Mohit
    Stevens, Don
    Gunawardena, Sriya W.
    Lutska, Yana
    Qi, Keqin
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas
    Rifkin, Robert M.
    BLOOD, 2018, 132
  • [39] A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell J.
    Reece, Donna
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Deng, Wei
    Kroog, Glenn
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [40] Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)
    Yimer, Habte
    Melear, Jason
    Faber, Edward
    Bensinger, William I.
    Burke, John M.
    Gunawardena, Sriya
    Sean, Murphy
    Parros, Hollee
    Lutska, Yana
    Darif, Mohamed
    Londhe, Anil
    Qi, Ming
    Ukropec, Jon
    Lin, Thomas
    Rifkin, Robert M.
    BLOOD, 2017, 130
12345